(Q39944711)

15 September 2017

title

Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours (English)

1 reference

15 September 2017

6

1 reference

15 September 2017

Irene J Virgolini

1

1 reference

15 September 2017

Michael Gabriel

2

1 reference

15 September 2017

Elisabeth von Guggenberg

3

1 reference

15 September 2017

Daniel Putzer

4

1 reference

15 September 2017

Dorota Kendler

5

1 reference

15 September 2017

publication date

1 September 2009

1 reference

European Journal of Cancer

15 September 2017

published in

1 reference

15 September 2017

volume

45 Suppl 1

1 reference

15 September 2017

page(s)

274-291

1 reference

Gastroenteropancreatic neuroendocrine tumours

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Chemotherapy for gastro-enteropancreatic endocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Cloning and characterization of a fourth human somatostatin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Substance-P receptors in human primary neoplasms: tumoral and vascular localization

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Somatostatin receptor: scintigraphy and radionuclide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

[99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Visualization of the thymus by substance P receptor scintigraphy in man

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

The diagnosis and management of malignant phaeochromocytoma and paraganglioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Somatostatin-receptor imaging in the localization of endocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

In vitro and in vivo studies of three radiolabelled somatostatin analogues:123I-Octreotide (OCT),123I-Tyr-3-OCT and111In-TIRA-d-Phe-1-OCT

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

What can gallium-68 PET add to receptor and molecular imaging?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Gastrointestinal carcinoids: the evolution of diagnostic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Targeting CCK receptors in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Dosimetry for Fractionated 131I-mIBG Therapies in Patients with Primary Resistant High-Risk Neuroblastoma: Preliminary Results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Clinical review: Current treatment of malignant pheochromocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Clinical and in vitro studies of imatinib in advanced carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970042-5

7 January 2021

10.1016/S0959-8049(09)70042-5

Identifiers

DOI

1 reference

15 September 2017

1 reference